EP1224262A2 - Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells - Google Patents
Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cellsInfo
- Publication number
- EP1224262A2 EP1224262A2 EP00968813A EP00968813A EP1224262A2 EP 1224262 A2 EP1224262 A2 EP 1224262A2 EP 00968813 A EP00968813 A EP 00968813A EP 00968813 A EP00968813 A EP 00968813A EP 1224262 A2 EP1224262 A2 EP 1224262A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- cell
- lin
- dcp
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 140
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 title claims abstract description 17
- 238000012512 characterization method Methods 0.000 title description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 238000012258 culturing Methods 0.000 claims abstract description 9
- 239000002243 precursor Substances 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 167
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 230000002187 allostimulatory effect Effects 0.000 claims description 18
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 17
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 238000005119 centrifugation Methods 0.000 claims description 15
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 13
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 13
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 12
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 12
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 11
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 11
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 11
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 11
- 101150013553 CD40 gene Proteins 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 239000012679 serum free medium Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 2
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 230000035800 maturation Effects 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 30
- 210000002540 macrophage Anatomy 0.000 description 23
- 210000001616 monocyte Anatomy 0.000 description 23
- 210000003719 b-lymphocyte Anatomy 0.000 description 21
- 239000011324 bead Substances 0.000 description 18
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 16
- 230000000735 allogeneic effect Effects 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 11
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 230000000139 costimulatory effect Effects 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011124 ex vivo culture Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000002458 cell surface marker Substances 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- -1 CD86 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000005135 veiled cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
Definitions
- the present invention relates to a dendritic cell (DC) composition, methods of isolating and culturing human peripheral blood mononuclear cells (PBMC) to obtain such a DC composition, methods of identifying and isolating DC at two different stages of maturation [the DC precursor (DCP) stage and the mature DC stage].
- the invention further relates to methods of activating T-cells employing a DC composition.
- Literature reports indicate that different researchers employ a diverse array of techniques for isolation and in vitro generation of antigen presenting cells (APC), many of which are labor intensive. There are numerous cell types that have been designated APC and protocols for isolating and activating them in vitro cultures. In addition, within a given APC type, there are variations with regard to isolation and activation procedures. This is particularly true with respect to DC, which function very effectively as APC.
- APC antigen presenting cells
- DC have been isolated and purified using a variety of methodologies incorporating, for example, multiple-step density-gradient based isolation, monoclonal antibody panning, depletion of lineage positive cells and serum-supplemented cultures (Macatonia, S.E., et al.,
- the invention includes, in one aspect, a method for obtaining, from a human blood sample, DC characterized by (i) a phenotype that is positive for surface Ag HLA-DR (human leukocyte Ag DR) and negative for surface antigens specific to particular cell lineages (i.e., CD3, CD14, CD16, CD19, CD20 and CD56 negative; designated herein as , "lin -”), and (ii) the ability to elicit primary and secondary immune responses when co-cultured with human lymphocytes.
- a phenotype that is positive for surface Ag HLA-DR (human leukocyte Ag DR) and negative for surface antigens specific to particular cell lineages (i.e., CD3, CD14, CD16, CD19, CD20 and CD56 negative; designated herein as , "lin -"
- DCP and/or DC are obtained from peripheral blood by performing the steps of (1) standard leukapheresis; (2) buoyant density centrifugation either with a one-step or successive two-step procedure; and (3) culture of the cells ex vivo in serum free medium for 40 hours, in the absence of exogenously added cytokines.
- DCP can be enriched prior to the 40 hour culture period by positive selection of DR+ cells using DR immunomagnetic beads or equivalent selection methods, followed by depletion of T lymphocytes, monocytes/macrophages and B lymphocytes using CD3, CD4 and CD19 immunomagnetic beads or equivalent depletion methods, respectively.
- DC can also be further enriched by way of (4) post-culture enrichment by buoyant density centrifugation; and (5) depletion of monocytes/macrophages and B lymphocytes using CD 14 and CD 19 immunomagnetic beads with or without prior enrichment for DR+ cells.
- the invention includes DCP and DC obtained by the methods set forth above.
- the DC of the invention is characterized functionally as capable of priming naive helper and cytotoxic T lymphocytes and phenotypically as (1) negative for expression of lineage markers (lin -); (2) strongly positive for expression of CD 86 (CD 86++); and (3) positive for expression of HLA-DR (i.e., class II MHC, DR+), designated herein as "Lin-/CD86++/DR+”.
- the invention includes exposing DCP in vitro to a selected antigen during the 40 hour culture period in a manner effective to yield antigen-loaded dendritic cells.
- Exemplary antigens for preparing such antigen-loaded dendritic cells include HER- 2/neu and PA2024.
- the invention also provides dendritic cells and/or antigen-loaded dendritic cells for use as a medicament in treating a tumor in a subject.
- the invention further provides the use of a composition of dendritic cells and/or antigen- loaded dendritic cells for the manufacture of a medicament for immunizing a subject against a known tumor antigen.
- Figure 1 depicts the results of a mixed lymphocyte reaction (MLR), wherein various cell types within a culture of Ag-loaded mature DC were evaluated for their relative potency as stimulator cells.
- Cell populations analyzed include: PA undep (PA2024-loaded, undepleted, mature DC); PA-CD14 (PA2024-loaded mature DC culture from which CD14 cells were depleted); PA-CD 19 (PA2024- loaded mature DC culture from which CD 19 cells were depleted); and PA-CD 14/CD 19 (PA2024-loaded mature DC culture from which CD 14 and CD19 cells were depleted).
- PA undep PA2024-loaded, undepleted, mature DC
- PA-CD14 PA2024-loaded mature DC culture from which CD14 cells were depleted
- PA-CD 19 PA2024- loaded mature DC culture from which CD 19 cells were depleted
- PA-CD 14/CD 19 PA2024-loaded mature DC culture from which CD 14 and CD19 cells were depleted.
- the results of ⁇ H-TdR incorporation are presented
- Figure 2 depicts the Ag presenting capability of various populations of Ag-loaded mature DC.
- Cell populations analyzed are as indicated for Fig. 1, and the results of ⁇ H-TdR inco ⁇ oration are presented following incubation of each cell population (APC) with autologous T cells.
- Figures 3A-D depict the results of 3-color FACS analysis of DCP at 0 hours (A, B) and 40 hours (C, D), following staining with PerCP-DR, FITC-lineage and PE-CD86 antibodies.
- the Lin-/DR+ cells at 0 hours shown as gated in A are weakly positive for CD86 as shown in B, while Lin- DR+ cells at 40 hours shown as gated in C strongly express CD86 as shown in D, illustrating that DC with a Lin-/CD86++/DR+ phenotype is not present at 0 hours, but stains brightly with CD86 after 40 hours culture.
- Figure 4 depicts the results of a MLR, wherein HER-2/neu-loaded mature, mock sorted DC (“BA Mock sort”), HER-2/neu-loaded APC having a traditional APC phenotype (“BA Lin+/DR+”), and HER-2/neu- loaded DC with the phenotype described herein (“BA Lin- /86++/DR+”) were evaluated for their relative potency as stimulator cells.
- BA Mock sort HER-2/neu-loaded mature, mock sorted DC
- HER-2/neu-loaded APC having a traditional APC phenotype (“BA Lin+/DR+)
- HER-2/neu- loaded DC with the phenotype described herein (“BA Lin- /86++/DR+”
- Figure 5 depicts the results of a MLR, wherein: PA2024-loaded mature DC enriched by buoyant density centrifugation on BDS 56 ("PA 561 Unsorted"), PA2024-loaded APC having a traditional APC phenotype ("PA Lin+/DR+”), and PA2024 stimulated DC with the phenotype described herein. Lin-/86++/DR+ (“PA LinJ86++/DR+”) were evaluated for their relative potency as stimulator cells. The results of ⁇ H-TdR inco ⁇ oration are presented following incubation of each of the cell populations with allogeneic T cells.
- Figure 6 depicts the Ag presenting capability of the various cell populations described for Fig. 4, and cells cultured in the absence of Ag, with the results of ⁇ H-TdR inco ⁇ oration presented following incubation of each cell population with autologous T cells.
- Figure 7 depicts the Ag presenting capability of the various cell populations described for Fig. 5, and cells cultured in the absence of Ag, with the results of ⁇ H-TdR inco ⁇ oration presented following incubation of each cell population with autologous T cells.
- Figure 8 depicts the results of flow cytometric analysis of DCP.
- DCP were enriched for Lin-/DR+ cells using DR immunomagnetic beads, followed by depletion of T lymphocytes, monocytes/macrophages and B lymphocytes using CD3, CD4 and CD 19 immunomagnetic beads, respectively.
- DCP can be characterized phenotypically as lineage negative, weakly positive for CD86 (not strongly positive) and DR positive (LinJ86 ⁇ DR + ).
- the population can be enriched from approximately 0.5-1.0% (Fig. 8A, B) to approximately 50% (Fig. 8C, D), by carrying out the immunomagnetic selection and depletion steps set forth above.
- Figure 9 depicts the results of MLR wherein PA2024-loaded mature mock-sorted DC (PA2024 Mock-sort), PA2024-loaded FACS sorted CD54+ cells (PA2024 CD54+) and PA2024- loaded CD54- cells (PA2024 CD54-) were evaluated for their relative potency as stimulator cells.
- the results of ⁇ H-TdR inco ⁇ oration are presented following incubation of each of the cell populations with allogeneic T cells.
- Figure 10 depicts the Ag presenting capability of the various cell populations described for Figure 9 and cells cultured in the absence of Ag (w/o Ag), with the results of ⁇ H-TdR inco ⁇ oration presented following incubation of each cell population with autologous T cells.
- DCP peripheral blood cells which can mature into DC under suitable conditions. DCP typically have a non-dendritic mo ⁇ hology and are not competent to elicit a primary immune response as antigen presenting cells.
- Dendritic cells are matured DCP, which typically have a dendritic cell mo ⁇ hology, that is, they are large veiled cells which extend dendrites when cultured in vitro. When pulsed with Ag or peptide, such DC are capable of presenting Ag to naive T cells.
- Precursor antigen presenting cells are cells that, when exposed to an Ag or peptide, are capable of becoming APC and presenting Ag to T cells.
- Antigen presenting cells are cells which, when exposed to an Ag or peptide, can activate CD8 + cytotoxic T-lymphocytes (CTL) or CD4 + helper T-lymphocytes in an immune response.
- CTL cytotoxic T-lymphocytes
- CD4 + helper T-lymphocytes in an immune response.
- the term "professional antigen presenting cells” includes DC, monocytes/macrophages (CD14+ cells) and B lymphocytes (CD19+ cells).
- the term "lin -" refers to a cell population that is negative for cell surface expression of the lineage markers; CD3, CD14, CD16, CD19, CD20 and CD56.
- the term “allostimulatory” means capable of stimulating allogeneic T cells due to differences in MHC molecules expressed on the cell surface.
- the terms “CD 86 bright”, “CD 86++”, and “strongly CD 86 positive” mean the cells are strongly immunoreactive with antibodies specific to CD 86, i.e., the results of a flow cytometry analysis of cells stained with a fluorescently labeled anti-CD86 antibody indicate a fluorescence intensity that is one log greater than that of monocyte/macrophage or B cells stained with the same anti-CD 86 antibody, using the same procedure. Such cells are said to express CD 86 at a high level on the cell surface.
- Ag-loaded mature DC refers to a PBMC-derived cell culture enriched for DCP and cultured ex vivo in the presence of Ag, i.e., a tumor Ag.
- Such "Ag-loaded mature DC” include DC and various types of PBMC including professional APC such as monocytes/macrophages, which are positive for cell surface expression of CD 14, and B lymphocytes, which are positive for cell surface expression of CD 19.
- immunogen refers to a substance that is able to stimulate or induce a humoral antibody and/or cell-mediated immune response.
- Antigen refers to a substance that reacts alone or in the context of MHC molecules with the products of an immune response (e.g., antibodies, T-cell receptors) which have been stimulated by a specific immunogen. Antigens therefore include the specific immunogens giving rise to the response (e.g., antigenic peptides, proteins or polysaccharides) as well as the entities containing or expressing the specific immunogens (e.g., viruses, bacteria, etc.).
- Tumor antigens refer to tumor-associated Ag and tumor-specific Ag.
- tumor antigens include HER-2/neu, prostatic acid phosphatase (PAP) and any of a number of proteins and polysaccharides expressed by tumor cells.
- PAP prostatic acid phosphatase
- the term “mock sorted” refers to cells that have been stained with fluorescently labeled antibody and run through all the steps of a flow cytometry analysis or sorting procedure, but are not sorted.
- the present invention relates to the isolation, culture and characterization of DCP and
- the DC of the invention is not detected in freshly isolated PBMC or in fractions enriched for DCP, but appears during 40 hour ex vivo culture of DCP.
- the DC of the invention are both allostimulatory and capable of presenting Ag such as cancer Ag to autologous T cells.
- such a DC population may be obtained by: ( 1 ) leukapheresis of peripheral blood; (2) buoyant density centrifugation to enrich for DCP, either with a one-step or successive two-step procedure, (using buoyant density solution BDS 77 or BDS 77 and 65, respectively; Dendreon Co ⁇ .); and (3) culture of DCP ex vivo in serum free medium for 40 hours, in the presence of Ag and in the absence of exogenously added cytokines.
- DCP can be enriched prior to the 40 hour culture period by positive selection of DR+ cells using DR immunomagnetic beads or equivalent selection methods, followed by depletion of T lymphocytes, monocytes/macrophages and B lymphocytes using CD3, CD4 and CD 19 immunomagnetic beads or equivalent depletion methods, respectively.
- DC can also be further enriched by way of (4) post-culture enrichment by buoyant density centrifugation; and (5) depletion of monocytes/macrophages and B lymphocytes using CD 14 and CD 19 immunomagnetic beads with or without prior enrichment for DR+ cells.
- exemplary serum-free media for culturing the cell population containing DCP include
- Dulbecco's Modified Minimal Essential Medium F-12 (1:1), AIM-V, XVIVOIO XVIV015, XVIVO20, macrophage serum-free medium, nutrient-supplemented AIM-V or Enriched Monocyte SFM (available from, e.g., Gibco/BRL Life Technologies, Gaithersburg, MD).
- DC are cultured in serum-free and protein-free medium.
- the DCP cell population is characterized phenotypically as lineage negative, i.e., negative for expression of the cell-surface lineage markers CD3, CD14, CD16, CD19, CD20, and CD56; weakly positive for the cell surface marker CD86 (i.e., not strongly positive); and positive for cell surface expression of HLA DR (LinJCD86 ⁇ /DR+).
- the DC population is characterized as lineage negative, strongly positive for CD86 ("CD86-bright”); and positive for cell surface expression of HLA DR (Lin-/86++/DR+). This Lin-/86++/DR+ population is not detected in freshly isolated PBMC or in cell fractions enriched for DCP.
- DCP mature into a cell population which expresses additional phenotypic markers known to be associated with dendritic cell function, including DC-associated costimulatory and adhesion molecules such as CD la, CD1 lc, CD40, CD54, and CD80.
- the acquisition of the phenotype correlates with the functional maturation of DC, in that DCP become potent APC which are not only allostimulatory but also capable of presenting Ag, exemplified by prostate cancer Ag and breast cancer Ag, to autologous T cells.
- FACS-sorted Lin-/86++/DR+ cells demonstrated stronger responses than cultured B cells and monocytes/macrophages in allogeneic mixed leukocyte reaction (MLR) and Ag presentation assays (Example 3).
- MLR mixed leukocyte reaction
- Example 3 Ag presentation assays
- the purity of DC in this fraction may be quantified using, for example, flow cytometry (i.e., FACS) analysis, together with functional assays.
- flow cytometry i.e., FACS
- DC Historically DC have been characterized as negative for the cell surface markers CD3 (T-cells), CD14 (monocytes/macrophages), CD19/20 (B-cells), CD56 (NK cells) and positive for HLA class II expression.
- T-cells T-cells
- CD14 monocytes/macrophages
- B-cells B-cells
- CD56 NK cells
- HLA class II expression HLA class II expression
- DC are known to those of skill in the art as the most potent APC. They are the only APC capable of priming naive helper and cytotoxic T lymphocytes. Because of this unique ability, therapeutic applications of DC have been found to be promising in the treatment of cancer patients.
- DC represent a small, heterogeneous population of leukocytes found in various lymphoid and non-lymphoid organs at different differentiation/maturation stages. Identification of DC and DC lineage cells has been difficult because of their heterogeneity, scarcity in the peripheral blood and the lack of a DC-specific cell surface marker.
- DC have been typically identified by their characteristic dendritic mo ⁇ hology, potent Ag-presenting abilities, and their cell surface phenotype characterized by a panel of monoclonal antibodies (mAb) against several multi-lineage markers such as CDla, CD1 lb, CD1 lc, CD40, CD54, CD80, CD83, CD86, CD123 and upregulated MHC molecules.
- mAb monoclonal antibodies
- DCP collected from the peripheral blood of patients differentiate into mature Ag-loaded DC, designated herein as "Lin-/86++/DR+".
- Such mature Ag-loaded DC may be reinfused into patients, and induce in vivo immune responses directed to cancer Ag.
- DC in the Ag-loaded DC fraction typically have a dendritic mo ⁇ hology when cultured in vitro. Further, the cells are typically negative for lineage specific cell surface markers such as CD3, CD14, CD16, CD19, CD20 and CD56: positive for MHC class II, as evidenced by HLA-DR expression; and exhibit high level expression of the cell surface marker, CD86.
- lineage specific cell surface markers such as CD3, CD14, CD16, CD19, CD20 and CD56: positive for MHC class II, as evidenced by HLA-DR expression; and exhibit high level expression of the cell surface marker, CD86.
- CD 86 also known as "B7-2" is expressed on APC such as B cells and monocytes/macrophages.
- APC such as B cells and monocytes/macrophages.
- the expression of the costimulatory molecules B7.1 (CD80) and B7.2 (CD86) on APC is upregulated by the interaction between CD40 expressed on APC and CD40L expressed on T cells.
- CD80 and CD86 have been shown to bind to CD28 on T cells providing a costimulatory signal necessary for T cell activation.
- APC deliver, in addition to an Ag specific signal, several costimulatory signals that work in an additive manner.
- costimulation via CD80/CD86-CD28 is of critical importance
- the biological activity of various cell populations was evaluated in assays used by those of skill in the art to characterize DC.
- assays include, the mixed lymphocyte reaction or
- MLR wherein irradiated stimulator cells are cultured with allogeneic T cells (responders).
- the cells are cultured in medium containing ⁇ H-thymidine for the final 18 h of a 6-day incubation period, with ⁇ H-thymidine inco ⁇ oration measured as an indicator of responder cell proliferation.
- a second assay indicates the Ag presentation ability of the Ag-loaded cells based on the ability of irradiated cells to stimulate autologous T cells, measured as above for the MLR.
- the DC population described herein as "Lin- /86++/DR+”, are approximately 20-fold more stimulatory than monocytes/macrophages and B lymphocytes in an allogeneic MLR; and (2) the Lin-/86++/DR+ cells are capable of presenting tumor Ag to autologous T cells, with an Ag-presenting ability that is at least 20-fold that of monocyte /macrophages and B lymphocytes.
- the population of cells described herein as DCP can be characterized phenotypically as Lin- /86 ⁇ /DR+.
- the population of cells described herein as DC can be characterized phenotypically as Lin-/86++ DR+ and express all relevant molecules typically associated with DC on their cell surface.
- the cells are potent allostimulatory and Ag-presenting cells.
- the DCP and DC phenotypes described herein find utility in a number of applications, including, but not limited to: (1) quality control of cell processing and manufacturing in ex vivo generation of DC from bone marrow, PBMC, or other tissues and cell lines; (2) cellular immunotherapy; (3) clinical monitoring following DCP and/or DC mobilization, DC immunotherapy and other vaccination protocols; (4) utility as a diagnostic and prognostic tool; (5) utility in identification of DC-1, DC-2, and DC -3 sub-phenotypes; (6) utility in ex vivo and in vivo generation of T cells specific to naive or weak Ag; (7) utility in in vitro and in vivo models of disease states, e.g., rheumatoid arthritis, multiple myeloma, autoimmunity, cancer, viral, bacterial, and fungal infections; (8) a role in generation of immune chimeras for allo- and xeno- transplantation; (9) utility as an adjunct to HSC rescue therapy for graft-
- PBMC peripheral blood mononuclear cells
- BDS 77 Buoyant density solution (BDS) 77, Dendreon Co ⁇ .] or a successive two-step (BDS 77 and 65,
- Allogeneic T cells were enriched from buffy coat preparations derived from 9 healthy donors using the two-step buoyant density centrifugation procedure followed by affinity negative selection column chromatography (R&D Systems). Autologous T cells were enriched from apheresis products using the same method.
- mAb Monoclonal Antibodies
- the commercially available mAb used to stain DC and DCP for flow cytometry are: (1) the fluorescein (FITC) conjugated antibodies Lin 1 (BD), CD3 (BD), CD14 (BD), CD19 (BD), and IgGl (BD); (2) the PE-conjugated antibodies CD1 lc (BD), CD40 (Immunotech), CD54 (BD), CD80 (Pharmingen), CD83 (Pharmingen), CD86 (Pharmingen), IgGl (BD); and (3) the PerCP-conjugated antibodies HLA-DR (BD) and IgG2a (BD), wherein BD refers to Becton Dickinson.
- Antigens Two exemplary recombinant tumor Ags (Ag) evaluated herein were: (1) recombinant HER-2/neu, a fusion protein comprising a portion of the N-terminal extracellular domain and a smaller portion of the C-terminal intracellular domain of HER-2/neu and granulocyte macrophage-colony stimulating factor (GM-CSF) and (2) PA2024, a fusion protein consisting of prostatic acid phosphatase (PAP) and GM-CSF.
- PAP prostatic acid phosphatase
- DCP Ex vivo Culture Of DCP.
- DCP were cultured in teflon bags (American Fluoroseal) at a density of lxlO ⁇ /ml in AIM-V medium supplemented with 2 mM glutamine in a humidified incubator at 37°C under 5% CO2 for 40 hours.
- DCP were pulsed with Ag, recombinant HER-2/neu (20 ⁇ g/ l) or PA2024 (10 ⁇ g ml).
- Cell sorting was performed with a FACS Vantage I (Becton Dickinson) under sterile conditions. Cells labeled with FITC-Lin 1, PE-CD86, and PerCP-HLA DR were resuspended in PBS containing 2% human serum and bulk sorted at the flow rate of 5,000 - 10,000 cells/second. Sorting gates were determined using cells labeled with isotype-matched control Ab.
- DCP and/or DC were enriched for DR positive cells (DR+) using DR immunomagnetic beads (Miltenyi).
- DR+ DR positive cells
- Cells were resuspenderd in PBS containing 0.5% human serum, with or without 2mM EDTA, and mixed with the bead suspension at a 4: 1 ratio of cells/beads (v/v). After a 15 minute incubation at 4°C, DR+ cells are collected using column separation (Miltenyi).
- T-lymphocytes, monocytes/macrophages and B lymphocytes were depleted from pre- and post-culture cells using CD3, CD14 and CD19 immunomagnetic beads (Dynal), respectively.
- Cells and beads were resuspended in PBS containing 2% human serum and mixed at a 1 :5 ratio of cells:beads. After a 20 minute incubation at 4°C with gentle mixing, unadsorbed cells were collected and washed once in AIM- V.
- MLR MLR.
- Cells were irradiated at 3,000 rad and used as stimulators at 13 - 8x10 ⁇ cells/well in triplicate wells of round-bottom 96-well plates. As responders, 5x10 ⁇ allogeneic T cells were added to each well. One ⁇ Ci of ⁇ H-thymidine was added to each well for the final 18 hours of a 6-day incubation period. At the end of incubation, cells were harvested and ⁇ H- thymidine inco ⁇ oration measured. Wells containing either stimulators alone or responders alone served as controls.
- DCP were cultured ex vivo for 40 hours in the presence or absence of Ag.
- Cells were then either FACS-sorted or enriched for DC by immunomagnetic depletion of T-lymphocytes, monocytes/macrophages and B lymphocytes.
- Cells were then irradiated at 3,000 rad and their T cell stimulatory activity measured by incubating at 13 - 8xl ⁇ 5/well DC with lxlO ⁇ /well autologous T cells in triplicate wells of 96-well round-bottom palates. Proliferation of T cells was measured as above.
- Example 1 Culture and characterization of Ag-loaded DC Preparation of Ag-loaded mature DC involves the enrichment of DCP from PBMC and ex vivo culture of the precursors for 40 hours in serum free medium in the absence of exogenously added cytokines. The relative ability of various cell types found within a culture of Ag-loaded mature DC to act as stimulator cells was evaluated by depleting various cell types from the culture and determining the effect of depleted and control cells in a MLR and for their ability to present Ag to autologous T cells. Monocytes/macrophages and/or B lymphocytes were depleted from the mature DC culture using CD 14 and/or CD 19 immunomagnetic beads (Dynal), respectively.
- Example 2 CD86 expression on mature DC The pattern of CD86 expression on the surface of APC was evaluated during culture over a period of 40 hours.
- DCP enriched from PBMC by buoyant density centrifugation with or without further enrichment using immunomagnetic beads, as described above, were cultured in the presence a HER-2/neu or PA2024 tumor Ag for 40 hours in serum free medium in the absence of exogenously added cytokines.
- a moderate upregulation of CD86 was observed in the Lin+/DR+ cell population within the culture, the main constituents of which are monocytes/macrophages (CD 14+ cells) and B cells (CD 19+ cells).
- DC are known in the art to be the most potent APC, which are allostimulatory and capable of presenting Ag to naive T cells.
- Lin-/CD86++/DR+ population was compared to that of Lin+/DR+ cells in the context of allogeneic stimulation and Ag presentation.
- the Lin+/DR+ population includes monocytes/macrophages (CD 14+ cells) and B lymphocytes (CD 19+ cells), two types of professional APC.
- DCP were cultured in the presence of either recombinant HER-2/neu or PA2024, as described above, and the Lin-/86++/DR+ population was enriched by buoyant density centrifugation using BDS 56 (Dendreon Co ⁇ .). Cells collected from the interface were sorted by FACS, with the Lin-/86++/DR+ and the Lin+ DR+ cell populations collected.
- Each FACS-sorted population was tested for allostimulatory activity in a MLR using allogeneic T cells as responders and for the ability to present tumor Ag to autologous T cells.
- the Lin-/86++/DR+ cells sorted after culturing with either recombinant Her-2/neu or PA2024, demonstrated allostimulatory activity that could be detected with less than 100 stimulators/well.
- the potency of allostimulatory ability was calculated as EC50, the number of stimulators or APC required to elicit half-maximal T cell proliferation, with a lower EC50 indicative of a more potent APC.
- Cells with a Lin-/86++/DR+ phenotype had approximately 20-fold greater allostimulatory activity than Lin+/DR+ cells, mock-sorted cells or unsorted BDS 56 interface cells (Fig. 4 and 5).
- Table II indicates approximate EC50 values for allogeneic stimulation in an MLR by cells having a Lin-/86++/DR+ or Lin+/DR+ phenotype following incubation with the BA (HER-2/neu-GM-CSF) or PA2024 (prostatic acid phosphatase-GM-CSF) fusion protein.
- Lin-/CD86++/DR+ population was also compared to that of Lin+/DR+ cells in the context of autologous T cells.
- a FACS-sorted Lin-/86++/DR+ population also demonstrated a potent ability to present naive Ag.
- Her-2/neu- and PA2024-loaded Lin-/86++/DR+ cells were at least 20-fold more stimulatory to T cells than Her-2/neu- or PA2024-loaded Lin+/DR+ cells. (Fig. 6 and 7, Table III).
- Lin-/86++/DR+ population represent APC that are not only strongly allostimulatory but also capable of presenting naive tumor-associated Ag.
- DCP were enriched from leukapheresis products by buoyant density centrifugation. Cells were further enriched for Lin-/DR+ cells using DR immunomagnetic beads for selection of DR+ cells, followed by immunomagnetic depletion of T lymphocytes, monocytes/macrophages and B cells with CD3, CD14 and CD19 beads, respectively.
- Figure 8 shows that pre-culture Lin-/DR+ cells are weakly positive for CD86 (not strongly positive) and the DCP population is enriched typically from about 0.5-1.0% (Fig. 8A, B) to approximately 50% (8C, D), following immunomagnetic selection/depletion. The enriched DCP mature into DC (Fig.
- This population of matured DC expresses all relevant costimulatory molecules, including CDla, CDl lc, CD40, CD54 and CD80, associated with differentiated dendritic cell function.
- An adhesion molecule CD54 is expressed on APC including DC and plays a role in the activation of T cells by APC.
- CD54+ population was compared to that of a CD54- population in the context of allogeneic stimulation and Ag presentation.
- DCP were cultured in the presence of PA2024 at lO ⁇ g ml (as described above), and cells were sorted by FACS with the CD54+ and CD54- populations collected. Each sorted population was tested for allostimulatory activity in MLR (Fig. 9) and for the ability to present Ag to autologous T cells (Fig. 10). Mock-sorted cells and cells cultured in the absence of Ag were included in the assays as control APC.
- the PA2024-loaded CD54+ cells demonstrated allostimulatory and Ag presenting activity approximately 4- fold greater than that of mock-sorted cells (PA2024 Mock-sort).
- the PA2024-loaded CD54- cells were not active in either MLR or Ag presenting activity.
- unsorted cells cultured in the absence of Ag were not active in Ag presenting activity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15861899P | 1999-10-08 | 1999-10-08 | |
US158618P | 1999-10-08 | ||
PCT/US2000/027651 WO2001027245A2 (en) | 1999-10-08 | 2000-10-06 | Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1224262A2 true EP1224262A2 (en) | 2002-07-24 |
Family
ID=22568957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00968813A Withdrawn EP1224262A2 (en) | 1999-10-08 | 2000-10-06 | Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1224262A2 (en) |
JP (1) | JP2003511064A (en) |
AU (1) | AU7867400A (en) |
CA (1) | CA2385792A1 (en) |
HK (1) | HK1045329A1 (en) |
WO (1) | WO2001027245A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7097833B2 (en) | 2002-07-19 | 2006-08-29 | Boston Scientific Scimed, Inc. | Selected cell delivery for heart failure |
AU2002950778A0 (en) * | 2002-08-15 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of characterizing dendritic cells |
AU2003254382B2 (en) * | 2002-08-15 | 2008-11-13 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | A method of characterizing dendritic cells |
CA2528727A1 (en) * | 2003-06-10 | 2004-12-16 | The University Of Melbourne | Immunomodulating compositions, uses therefor and processes for their production |
WO2006006638A1 (en) * | 2004-07-08 | 2006-01-19 | Medinet Co., Ltd | DENDRITIC CELL, DRUG CONTAINING THE DENDRITIC CELL, THERAPEUTIC METHOD USING THE DENDRITIC CELL AND METHOD OF CULTURING ϜδT CELL |
EP2139498B1 (en) * | 2007-03-22 | 2015-03-18 | Dendreon Corporation | Methods for detecting a natural killer (nk) cell-mediated immune response and an increase in nk cell activity |
KR101349249B1 (en) * | 2007-08-24 | 2014-01-10 | (주)아모레퍼시픽 | In vitro skin sensitization test method |
WO2012123269A1 (en) | 2011-03-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Immunogenic compositions and methods for their use |
EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
EP3191109B1 (en) | 2014-09-10 | 2023-03-29 | Miltenyi Biotec B.V. & Co. KG | A cell population for use in treating cancer |
US11254914B2 (en) | 2015-03-12 | 2022-02-22 | Health Research, Inc. | Enrichment of CD16+ monocytes to improve dendritic cell vaccine quality |
WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
CN109679903A (en) * | 2019-01-16 | 2019-04-26 | 深圳咖荻生物科技有限公司 | Separation and purification method of T lymphocytes |
CN113151169A (en) * | 2021-05-14 | 2021-07-23 | 上海赛笠生物科技有限公司 | Method for separating natural killer cells based on magnetic bead positive selection strategy |
CN116103234B (en) * | 2023-04-13 | 2023-06-23 | 天津纽赛生物技术有限公司 | Preparation method and application of novel DC-like cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7659119B2 (en) * | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
EP0918847A2 (en) * | 1996-08-14 | 1999-06-02 | Nexell Therapeutics Inc. | Cytokine-free culture of dendritic cells |
AU1220599A (en) * | 1997-11-14 | 1999-06-07 | Hemosol Inc. | Method for the production and use of dendritic cells |
-
2000
- 2000-10-06 CA CA002385792A patent/CA2385792A1/en not_active Abandoned
- 2000-10-06 EP EP00968813A patent/EP1224262A2/en not_active Withdrawn
- 2000-10-06 AU AU78674/00A patent/AU7867400A/en not_active Abandoned
- 2000-10-06 JP JP2001530450A patent/JP2003511064A/en not_active Withdrawn
- 2000-10-06 WO PCT/US2000/027651 patent/WO2001027245A2/en not_active Application Discontinuation
-
2002
- 2002-09-14 HK HK02106764.9A patent/HK1045329A1/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0127245A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001027245A3 (en) | 2001-12-13 |
HK1045329A1 (en) | 2002-11-22 |
WO2001027245A2 (en) | 2001-04-19 |
CA2385792A1 (en) | 2001-04-19 |
JP2003511064A (en) | 2003-03-25 |
AU7867400A (en) | 2001-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
O'doherty et al. | Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. | |
Maraskovsky et al. | In vivo generation of human dendritic cell subsets by Flt3 ligand | |
Romani et al. | Generation of mature dendritic cells from human blood An improved method with special regard to clinical applicability | |
Kiertscher et al. | Human CD14+ leukocytes acquire the phenotype and function of antigen‐presenting dendritic cells when cultured in GM‐CSF and IL‐4 | |
Thurner et al. | Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application | |
Tuyaerts et al. | Generation of large numbers of dendritic cells in a closed system using Cell Factories™ | |
Schäkel et al. | A novel dendritic cell population in human blood: one‐step immunomagnetic isolation by a specific mAb (M‐DC8) and in vitro priming of cytotoxic T lymphocytes | |
Pickl et al. | Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. | |
Smit et al. | Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells | |
Duperrier et al. | Distinct subsets of dendritic cells resembling dermal DCs can be generated in vitro from monocytes, in the presence of different serum supplements | |
US6274378B1 (en) | Methods and compositions for obtaining mature dendritic cells | |
US7198948B2 (en) | Methods and compositions for obtaining mature dendritic cells | |
Takamizawa et al. | Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors. | |
KR20220113543A (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells | |
EP1224262A2 (en) | Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells | |
Santin et al. | Expression of surface antigens during the differentiation of human dendritic cells vs macrophages from blood monocytes in vitro | |
AU732536B2 (en) | New antigen presenting cells, a process for preparing the same and their use as cellular vaccines | |
Bella et al. | Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells? | |
WO2001039594A2 (en) | Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media | |
Schäkel et al. | M-DC8+ leukocytes–a novel human dendritic cell population | |
Lopez et al. | IL-13 induces CD34+ cells isolated from G-CSF mobilized blood to differentiate in vitro into potent antigen presenting cells | |
Mohty et al. | Generation of potent Th1 responses from patients with lymphoid malignancies after differentiation of B lymphocytes into dendritic‐like cells | |
Freudenthal et al. | Dendritic cells in human blood and synovial exudates | |
AU4226999A (en) | Method for preparation and (in vivo) administration of antigen presenting cell composition | |
AU2013206016B2 (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020508 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20041019 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050302 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1045329 Country of ref document: HK |